[Transforming growth factor-β and renal fibrosis]

Area of Science:

• Nephrology
• Molecular Biology
• Pathology

Background:

• Renal fibrosis, a hallmark of chronic kidney disease, is driven by Transforming Growth Factor-beta (TGF-β).
• TGF-β signaling pathways promote extracellular matrix synthesis and inhibit degradation, leading to fibrotic responses in various renal cells.
• Dysregulation of TGF-β signaling, particularly involving Smad3, is central to kidney fibrosis pathogenesis.

Purpose of the Study:

• To elucidate the role of TGF-β in renal fibrosis.
• To explore the interplay of TGF-β with other signaling pathways in kidney injury.
• To identify potential therapeutic targets for fibrotic kidney disease by focusing on downstream effectors.

Main Methods:

• Review and synthesis of current literature on TGF-β signaling in renal fibrosis.
• Analysis of canonical and non-canonical TGF-β pathways.
• Investigation of Smad3 as a key pathological gene and epigenetic regulation in TGF-β/Smad3 signaling.

Main Results:

• TGF-β induces apoptosis, proliferation, and fibrotic responses in renal cells (epithelial cells, endothelial cells, podocytes, fibroblasts, pericytes, macrophages).
• TGF-β promotes myofibroblast transdifferentiation, activation, and proliferation.
• TGF-β interacts with BMP-7, Wnt/β-catenin, and MAP kinase pathways to exert profibrotic effects.

Conclusions:

• Directly targeting TGF-β may lead to adverse effects like tumorigenesis and immune diseases.
• Modulating the balance of downstream Smad3 and Smad7 offers a promising therapeutic approach.
• Targeting the TGF-β/Smad3 pathway may prevent or delay the progression of fibrotic kidney disease.